Consensus SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
44 ^USD	+2.59%		+1.38%	+20.55%

Mar. 12	Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
Mar. 06	JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	MT

Evolution of the average Target Price on SpringWorks Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a95b78a31f40642fa.UPot_PDKvGpc3vSPsPpZiw-gjRf277fsCmX0Z8cQWME.GcpqyKek0QYvn47724Nh6ULwv0ipwsG9QgekE_VcEaZmiV6MsaOPCSqSoQ~72c5fa527fe0f49d5efe3dc0e83563ac

Analyst Recommendations on SpringWorks Therapeutics, Inc.

JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	Mar. 06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	Mar. 06	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	Feb. 26	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	Feb. 07	MT
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	Jan. 25	MT
Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating	Nov. 29	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $73 From $64, Keeps Buy Rating	Nov. 29	MT
HC Wainwright Raises SpringWorks Therapeutics' Price Target to $64 From $52, Buy Rating Kept	Nov. 28	MT
HC Wainwright Adjusts SpringWorks Therapeutics' Price Target to $52 From $58, Maintains Buy Rating	Nov. 20	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $58 From $66, Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $66 From $105, Keeps Buy Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on SpringWorks Therapeutics to $49 From $43, Maintains Buy Rating	23-07-20	MT
Barclays Adjusts Price Target on SpringWorks Therapeutics to $41 From $55, Keeps Overweight Rating	23-04-28	MT
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $57 From $53, Maintains Overweight Rating	23-03-07	MT
HC Wainwright Adjusts SpringWorks Therapeutics Price Target to $105 From $99, Maintains Buy Rating	23-03-07	MT
Goldman Sachs Raises SpringWorks Therapeutics' Price Target to $45 From $40, Maintains Buy Rating	23-01-26	MT
BofA Securities Starts SpringWorks Therapeutics at Buy With $45 Price Target	22-12-01	MT
Wedbush Cuts SpringWorks Therapeutics' Price Target to $45 From $52, Keeps Outperform Rating	22-11-23	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $99 From $103, Maintains Buy Rating	22-11-04	MT
Goldman Sachs Lowers SpringWorks Therapeutics Price Target to $40 From $44, Maintains Buy Rating	22-11-03	MT
Wedbush Adjusts SpringWorks Therapeutics Price Target to $52 From $53, Maintains Outperform Rating	22-11-03	MT
Goldman Sachs Adjusts Price Target on SpringWorks Therapeutics to $44 From $51, Keeps Buy Rating	22-10-21	MT
HC Wainwright Adjusts SpringWorks Therapeutics' Price Target to $103 from $94, Maintains Buy Rating	22-09-12	MT
HC Wainwright Trims Price Target on SpringWorks Therapeutics to $94 From $95, Reiterates Buy Rating	22-08-09	MT
Goldman Sachs Adjusts Price Target for SpringWorks Therapeutics to $51 From $52, Maintains Buy Rating	22-08-05	MT